HC Wainwright ups Bionomics to buy, cites positive data for PTSD drug (BNOX)
monsitj HC Wainwright has upgraded Bionomics (NASDAQ:BNOX) to buy, citing the company’s positive Phase 2 data for its drug candidate BNC210 in the treatment of post-traumatic stress disorder, or PTSD. The investment bank said the…
